Farallon Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-6,000
| Closed | -$241K | – | 96 |
|
|
2026
Q1 | $241K | Buy |
+6,000
| New | +$129K | ﹤0.01% | 131 |
|
|
2024
Q3 | – | Sell |
-6,000
| Closed | -$230K | – | 166 |
|
|
2024
Q2 | $230K | Hold |
6,000
| – | – | ﹤0.01% | 128 |
|
|
2024
Q1 | $353K | Hold |
6,000
| – | – | ﹤0.01% | 129 |
|
|
2023
Q4 | $359K | Sell |
6,000
-188,053
| -97% | -$9.54M | ﹤0.01% | 117 |
|
|
2023
Q3 | $7.38M | Buy |
194,053
+154,000
| +384% | +$6.76M | 0.03% | 93 |
|
|
2023
Q2 | $3.65M | Sell |
40,053
-277,500
| -87% | -$23.9M | 0.02% | 111 |
|
|
2023
Q1 | $20.9M | Sell |
317,553
-132,847
| -29% | -$7.67M | 0.11% | 81 |
|
|
2022
Q4 | $23.3M | Sell |
450,400
-27,600
| -6% | -$1.46M | 0.14% | 78 |
|
|
2022
Q3 | $32.6M | Buy |
+478,000
| New | +$28.3M | 0.18% | 83 |
|
|
2021
Q3 | – | Sell |
-1,550,000
| Closed | -$98M | – | 302 |
|
|
2021
Q2 | $98M | Sell |
1,550,000
-625,000
| -29% | -$32.3M | 0.4% | 55 |
|
|
2021
Q1 | $93.3M | Sell |
2,175,000
-100,000
| -4% | -$4.73M | 0.46% | 51 |
|
|
2020
Q4 | $130M | Hold |
2,275,000
| – | – | 0.78% | 42 |
|
|
2020
Q3 | $68.6M | Buy |
2,275,000
+25,000
| +1% | +$747K | 0.47% | 54 |
|
|
2020
Q2 | $73.5M | Buy |
2,250,000
+250,000
| +13% | +$8.03M | 0.59% | 46 |
|
|
2020
Q1 | $53.6M | Buy |
2,000,000
+1,500,000
| +300% | +$53.3M | 0.46% | 42 |
|
|
2019
Q4 | $15.3M | Buy |
+500,000
| New | +$13.8M | 0.1% | 93 |
|
Other funds holding APLS
Farallon Capital Management's APLS Position: Q2 2026 in Review
Farallon Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 6,000 shares — an estimated $241K sold.
Farallon Capital Management first reported a position in APLS in Q4 2019 and held it in 16 quarters. The position peaked at $130M in Q4 2020. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Farallon Capital Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Farallon Capital Management sold 6,000 Apellis Pharmaceuticals shares in Q2 2026, an estimated $241K.
- Farallon Capital Management first reported a position in Apellis Pharmaceuticals in Q4 2019 and held it in 16 quarters.
- Farallon Capital Management's Apellis Pharmaceuticals position peaked at $130M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.